Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
Copyright policy )Drug Development and Medicinal Chemistry Efforts toward SARS‐Coronavirus and Covid‐19 Therapeutics
AbstractThe COVID‐19 pandemic caused by SARS‐CoV‐2 infection is spreading at an alarming rate and has created an unprecedented health emergency around the globe. There is no effective vaccine or approved drug treatment against COVID‐19 and other pathogenic coronaviruses. The development of antiviral agents is an urgent priority. Biochemical events critical to the coronavirus replication cycle provided a number of attractive targets for drug development. These include, spike protein for binding to host cell‐surface receptors, proteolytic enzymes that are essential for processing polyproteins into mature viruses, and RNA‐dependent RNA polymerase for RNA replication. There has been a lot of ground work for drug discovery and development against these targets. Also, high‐throughput screening efforts have led to the identification of diverse lead structures, including natural product‐derived molecules. This review highlights past and present drug discovery and medicinal‐chemistry approaches against SARS‐CoV, MERS‐CoV and COVID‐19 targets. The review hopes to stimulate further research and will be a useful guide to the development of effective therapies against COVID‐19 and other pathogenic coronaviruses.
- University Federico II of Naples Italy
- Purdue University West Lafayette United States
Models, Molecular, Chemistry, Pharmaceutical, Pneumonia, Viral, coronavirus, protease inhibitors, Biochemistry, Antiviral Agents, drug discovery, Drug Development, Models, Drug Discovery, Humans, Protease Inhibitors, Viral, General Pharmacology, Toxicology and Pharmaceutics, Pandemics, Pharmacology, coronavirus; Covid-19; drug discovery; protease inhibitors; SARS-CoV; Antiviral Agents; Chemistry, Pharmaceutical; Coronavirus Infections; Drug Discovery; Humans; Models, Molecular; Pandemics; Pneumonia, Viral; Protease Inhibitors; Drug Development, Organic Chemistry, Molecular, COVID-19, SARS-CoV, Pneumonia, Chemistry, Pharmaceutical, Molecular Medicine, Covid-19, Coronavirus Infections
Models, Molecular, Chemistry, Pharmaceutical, Pneumonia, Viral, coronavirus, protease inhibitors, Biochemistry, Antiviral Agents, drug discovery, Drug Development, Models, Drug Discovery, Humans, Protease Inhibitors, Viral, General Pharmacology, Toxicology and Pharmaceutics, Pandemics, Pharmacology, coronavirus; Covid-19; drug discovery; protease inhibitors; SARS-CoV; Antiviral Agents; Chemistry, Pharmaceutical; Coronavirus Infections; Drug Discovery; Humans; Models, Molecular; Pandemics; Pneumonia, Viral; Protease Inhibitors; Drug Development, Organic Chemistry, Molecular, COVID-19, SARS-CoV, Pneumonia, Chemistry, Pharmaceutical, Molecular Medicine, Covid-19, Coronavirus Infections
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).254 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 0.1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
Citations provided by BIP!Popularity provided by BIP!